Extracellular Vesicles – VJRegenMed

EV-based therapies for myocardial infarction

Simon Ng — Wed, 19 Jan 2022 13:01:32 +0000

Marta Monguió-Tortajada, PhD, Health Science Research Institute Germans Trias i Pujol (IGTP), Badalona, Spain, comments on utilizing extracellular vesicles (EVs) derived from mesenchymal stem cells to regenerate cardiac tissue after a myocardial infarction. EVs that were found to promote angiogenesis and reduce inflammation were identified and with a tissue-engineered scaffold, were delivered to scar tissue. After a period of 30 days, fibrosis was reduced and increased cardiac function was observed. This interview took place at the 6th World Congress of the Tissue Engineering and Regenerative Medicine International Society (TERMIS 2021).

The benefits of extracellular vesicle-based therapies

Simon Ng — Wed, 19 Jan 2022 13:01:30 +0000

Marta Monguió-Tortajada, PhD, Health Science Research Institute Germans Trias i Pujol (IGTP), Badalona, Spain, discusses the advantages of using extracellular vesicles (EVs) in tissue-engineered therapies. EVs tend to require less stringent storage conditions and as they are not live, they are more stable compared to cellular therapies. They can also be formulated into a slow-release dosage, resulting in a lower dose required for administration, and in vivo models have demonstrated mesenchymal stem cell-derived EVs have an acceptable safety profile. This interview took place at the 6th World Congress of the Tissue Engineering and Regenerative Medicine International Society (TERMIS 2021).

Highlights in extracellular vesicle research at TERMIS 2021

Simon Ng — Mon, 10 Jan 2022 16:16:57 +0000

Marta Monguió-Tortajada, PhD, Health Science Research Institute Germans Trias i Pujol (IGTP), Badalona, Spain, provides her highlights from the 6th World Congress of the Tissue Engineering and Regenerative Medicine International Society (TERMIS 2021) within the field of extracellular vesicles (EVs). Dr Monguió-Tortajada discusses novel research on certain EVs which are attached to the extracellular matrix (ECM), and how these particular EVs can influence the cell environment and other EVs within the cell. This interview took place at TERMIS 2021.

Extracellular vesicles as a source of novel biomarkers

Simon Ng — Mon, 10 Jan 2022 16:16:57 +0000

Marta Monguió-Tortajada, PhD, Health Science Research Institute Germans Trias i Pujol (IGTP), Badalona, Spain, gives an overview of how extracellular vesicles (EVs) can be utilized to find novel biomarkers for cardiovascular diseases. EVs contain numerous molecules including proteins, microRNA, and non-coding RNAs that are protected from the extracellular environment, which can be utilized as biomarkers. This interview took place at the 6th World Congress of the Tissue Engineering and Regenerative Medicine International Society (TERMIS 2021).

Challenges with developing regenerative therapies for musculoskeletal disorders

Simon Ng — Thu, 06 Jan 2022 16:53:11 +0000

Jiao Jiao Li, PhD, University of Technology Sydney, Sydney, Australia, describes issues developing regenerative therapies for musculoskeletal disorders. Finding suitable materials with the correct properties for bioprinting remains a major hurdle, and whilst induced pluripotent stem cells (iPSCs) have shown promise in cellular therapies, more research is required for successful clinical adaptation. Dr Li additionally highlights how regulatory authorities may have difficulties classifying novel products such as extracellular vesicles (EVs), due to their complexity, as well as problems relating to large scale manufacturing of tissue-engineered therapies. This interview took place at the 6th World Congress of the Tissue Engineering and Regenerative Medicine International Society (TERMIS 2021).

TERMIS 2021 highlights: Extracellular vesicles

Simon Ng — Thu, 06 Jan 2022 16:53:10 +0000

Jiao Jiao Li, PhD, University of Technology Sydney, Sydney, Australia, emphasizes the need to focus on extracellular vesicles (EVs) at the 6th World Congress of the Tissue Engineering and Regenerative Medicine International Society (TERMIS 2021). She highlights the potential research that will be carried out in the field of EVs, as well as the incorporation of technologies such as biosensors and artificial intelligence in the development of tissue-engineered therapies. This interview took place at TERMIS 2021.

Delivering drugs to the CNS with extracellular vesicles

Simon Ng — Wed, 05 Jan 2022 17:32:21 +0000

Anne des Rieux, PhD, Université catholique de Louvain, Louvain, Belgium, discusses promising research within extracellular vesicles (EVs) for the treatment of central nervous system (CNS) diseases. Whilst EVs have been previously been investigated as diagnostic tools, current research suggests EVs can play a role in drug delivery. EVs, which contain various lipids, proteins and mRNA, can cross the blood-brain barrier, which is advantageous for the delivery of drugs to the brain. This interview took place at the 6th World Congress of the Tissue Engineering and Regenerative Medicine International Society (TERMIS 2021).

The potential of vesicular secretome fraction in hearing loss

admin_vjr_user — Thu, 26 Aug 2021 14:05:30 +0000

Eva Rohde, MD, Medical University Salzburg, Salzburg, Austria, describes ongoing research evaluating the therapeutic potential of the vesicular secretome fraction (VSF) in hearing loss. A single patient with Meniere’s disease, a condition of the inner ear, received a co-injection of VSF in one ear during surgical cochlear implantation, which resulted in a slight improvement in cochlear electrode function and no short- or long-term adverse events. The initiation of a Phase I safety clinical trial is pending, depending on the outcomes of ongoing pre-clinical safety testing, including biodistribution and toxicology assays. This interview took place during the International Society for Cell & Gene Therapy (ISCT) Annual Meeting 2021.

Promising avenues in extracellular vesicle-based therapeutics

admin_vjr_user — Tue, 24 Aug 2021 13:06:54 +0000

Eva Rohde, MD, Medical University Salzburg, Salzburg, Austria, provides an overview of the current landscape of research into extracellular vesicle (EV)-based therapeutics. She notes that in the last decade, the field has moved from basic, discovery research towards translation into the clinic, with a number of approaches currently being evaluated in clinical trials. Dr Rohde describes a number of EV-based therapeutic strategies under investigation, including the use of mesenchymal stromal cell (MSC)-derived EVs in neurodegenerative disorders, as well as the use of EVs in bone and tendon regeneration. This interview took place during the International Society for Cell & Gene Therapy (ISCT) Annual Meeting 2021.

Remaining barriers to the translation of EV-based therapies

admin_vjr_user — Tue, 24 Aug 2021 13:06:53 +0000

Eva Rohde, MD, Medical University Salzburg, Salzburg, Austria, considers some of the major bottlenecks that need to be addressed in order to drive the translation of extracellular vesicle-derived therapeutics to the clinic. She highlights the importance of collecting comparable preclinical data, the thorough preclinical characterization of EVs and secreted factors, as well an early focus on Chemistry, Manufacturing, and Control (CMC) processes. This interview took place during the International Society for Cell & Gene Therapy (ISCT) Annual Meeting 2021.